Article

Segment 5 - Value-based Decisions in NSCLC

Dr Peskin discusses programs such as Choosing Wisely and how providers must be mindful of high value, cost-conscious, cost-aware care.

Dr Peskin discusses programs such as Choosing Wisely and how providers must be mindful of “high value, cost-conscious, cost-aware” care. This ensures that only appropriate treatments are administered to patients with cancer.

Dr Sugarbaker suggests to the fellow panelists that the majority of NSCLC patients are not candidates for surgery because they are diagnosed too late for a procedure. Early detection would save a lot of money.

“The issue of imaging and early detection certainly resonates with payers, including myself, and not only economic but ethical considerations,” says Dr Peskin. He adds that while people gravitate toward the terms “targeted” and “precision,” one must verify that those treatments are used by clinicians and oncologists judicially.

Related Videos
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
Sandra Cuellar, PharmD
Screenshot of Adam Colborn, JD during an interview
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo